Her plasmid DNA vaccine-ZyCoV-D (JyCoV-D) has been found to be safe in two-phase trials to prevent corona. So, in a release issued by the Ministry of Science and Technology on Sunday, the Drug Regulatory Body Drugs Controller General of India (DCGI) started the Ahmedabad-based drug firm Zydus Cadila to start a clinical trial of Phase-lll of its Covid-19 vaccine ZyCoV-D. Is allowed.
The ministry reported that Zydus Cadila had completed a clinical trial of Phase 1/2 of this DNA vaccine candidate in India, with more than 1,000 participants and interim data showing that the vaccine is safe and immunogenic.
The third phase approval of the country's first potentially indigenously developed DNA vaccine against COVID-19 showed a great hope. The ministry said that on the basis of the recommendations of the subject expert committee to study the interim data, DCGI has approved to conduct Phase three clinical trials in 26,000 Indian participants.
The National Biopharma Mission (NBM), under the aegis of the Biotechnology Industry Research Assistance Council (BIRAC), a public sector undertaking under the Department of Biotechnology, has provided support for potential vaccines. DBT Secretary and BIRAC President Renu Swaroop expressed happiness that the vaccine is showing positive results. Apart from this, it will continue to give such positive results.
